Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
CAR T cell and multiple myeloma cell

Investigational arlocabtagene autoleucel (arlo-cel) research in relapsed/refractory multiple myeloma (RRMM)1

A phase 3 trial comparing arlo-cel to standard of care is open for enrollment1

Find Out More See arlo-cel MOA

Explore Investigational arlo-cel Clinical Trials​

Arlo-cel phase 2 study2

Arlo-cel phase 3 study1,3

Magnifying glass with checkmark

Find a QUINTESSENTIAL-2 clinical trial location​

CAR=chimeric antigen receptor; DPd=daratumumab + pomalidomide + dexamethasone; Kd=carfilzomib + dexamethasone; MOA=mechanism of action.

References: 1. A study to compare the efficacy and safety of BMS-986393 versus standard regimens in adult participants with relapsed or refractory and lenalidomide-exposed multiple myeloma (QUINTESSENTIAL-2). ClinicalTrials.gov identifier: NCT06615479. Updated February 10, 2026. Accessed February 13, 2026. https://clinicaltrials.gov/study/NCT06615479 2. Study of arlocabtagene autoleucel (BMS-986393) a GPRC5D-directed CAR T cell therapy in adult participants with relapsed or refractory multiple myeloma (QUINTESSENTIAL). ClinicalTrials.gov identifier: NCT06297226. Updated February 10, 2026. Accessed February 13, 2026. https://clinicaltrials.gov/study/NCT06297226 3. Popat R, Larson SM, Varshavsky-Yanovsky A, et al. QUINTESSENTIAL-2: a phase 3 study comparing efficacy and safety of arlocabtagene autoleucel (arlo-cel) versus standard regimens in adult patients with relapsed or refractory multiple myeloma (RRMM) refractory to lenalidomide. J Clin Oncol. 2025;43(16)(suppl):TPS7564. doi:10.1200/JCO.2025.43.16_suppl.TPS7564

This website is for US physicians to provide general information about ongoing BMS clinical trials and as an exchange of scientific information related to arlocabtagene autoleucel. Arlocabtagene autoleucel is not currently approved in any market and has not been evaluated by the FDA as safe or effective for multiple myeloma.

© 2026 Bristol-Myers Squibb Company.

HE-US-2600163 2/26